Sante Capital Fund’s Bionano Genomics BNGO Stock Holding History

Sante Capital Fund’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-114	Closed	-$501K	–	45
2021 Q2	$501K	Buy	+114	New	+$450K	0.21%	100

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Sante Capital Fund's BNGO Position: Q3 2021 in Review

Sante Capital Fund sold out of Bionano Genomics (BNGO) in Q3 2021, closing a stake of 114 shares — an estimated $501K sold.

Sante Capital Fund first reported a position in BNGO in Q2 2021 and held it in 1 quarter. The position peaked at $501K in Q2 2021. 147 funds tracked by Wall St. Rank hold BNGO as of Q3 2021.

Sante Capital Fund reported no remaining Bionano Genomics position as of Q3 2021 after selling out during the quarter.
Sante Capital Fund sold 114 Bionano Genomics shares in Q3 2021, an estimated $501K.
Sante Capital Fund first reported a position in Bionano Genomics in Q2 2021 and held it in 1 quarter.
Sante Capital Fund's Bionano Genomics position peaked at $501K in Q2 2021.
147 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2021.

Based on Sante Capital Fund's 13F filing for Q3 2021, filed 15 Nov 2021.